Anzahl der Einträge: 2.
Artikel
Livingstone, Elisabeth,
Zimmer, Lisa,
Hassel, Jessica C,
Fluck, Michael,
Eigentler, Thomas K ![ORCID 0000-0003-0019-2770](/images/orcid_16x16.gif)
,
Loquai, Carmen,
Haferkamp, Sebastian,
Gutzmer, Ralf,
Meier, Friedegund ![ORCID 0000-0003-4340-9706](/images/orcid_16x16.gif)
,
Mohr, Peter,
Hauschild, Axel,
Schilling, Bastian,
Menzer, Christian ![ORCID 0000-0002-1506-0191](/images/orcid_16x16.gif)
,
Kiecker, Felix,
Dippel, Edgar,
Roesch, Alexander,
Ziemer, Mirjana,
Conrad, Beate,
Körner, Silvia,
Windemuth-Kieselbach, Christine,
Schwarz, Leonora,
Garbe, Claus,
Becker, Jürgen C,
Schadendorf, Dirk,
Livingstone, Elisabeth,
Zimmer, Lisa,
Hassel, Jessica C,
Fluck, Michael,
Eigentler, Thomas K,
Loquai, Carmen,
Haferkamp, Sebastian,
Gutzmer, Ralf,
Meier, Friedegund,
Mohr, Peter,
Hauschild, Axel,
Schilling, Bastian,
Menzer, Christian,
Kiecker, Felix,
Dippel, Edgar,
Roesch, Alexander,
Ziemer, Mirjana,
Conrad, Beate,
Körner, Silvia,
Simon, Jan-Christoph,
Herbst, Rudolf A,
Berking, Carola,
Utikal, Jochen,
Sell, Sabine,
Martens, Uwe M,
Terheyden, Patrick,
Stadler, Rudolf,
Windemuth-Kieselbach, Christine,
Schwarz, Leonora,
Garbe, Claus,
Becker, Jürgen C und
Schadendorf, Dirk
(2022)
Adjuvant nivolumab plus ipilimumab or nivolumab alone versus placebo in patients with resected stage IV melanoma with no evidence of disease (IMMUNED): final results of a randomised, double-blind, phase 2 trial.
The Lancet 400 (10358), S. 1117-1129.
Volltext nicht vorhanden.
Zimmer, Lisa,
Livingstone, Elisabeth,
Hassel, Jessica C.,
Fluck, Michael,
Eigentler, Thomas,
Loquai, Carmen,
Haferkamp, Sebastian,
Gutzmer, Ralf,
Meier, Friedegund,
Mohr, Peter,
Hauschild, Axel,
Schilling, Bastian,
Menzer, Christian,
Kieker, Felix,
Dippel, Edgar,
Rösch, Alexander,
Simon, Jan-Christoph,
Conrad, Beate,
Körner, Silvia,
Windemuth-Kieselbach, Christine,
Schwarz, Leonora,
Garbe, Claus,
Becker, Jürgen C.,
Schadendorf, Dirk,
Berking, Carola,
Herbst, Rudolf A.,
Martens, Uwe M.,
Sell, Sabine,
Stadler, Rudolf,
Terheyden, Patrick und
Utikal, Jochen
(2020)
Adjuvant nivolumab plus ipilimumab or nivolumab monotherapy versus placebo in patients with resected stage IV melanoma with no evidence of disease (IMMUNED): a randomised, double-blind, placebo-controlled, phase 2 trial.
The Lancet 395 (10236), S. 1558-1568.
Volltext nicht vorhanden.
Diese Liste wurde erzeugt am Wed Jul 17 00:53:29 2024 CEST.